AMX-0035 for amyotrophic lateral sclerosis (ALS) – FDA Advisory Committee update
September 7, 2022 - The FDA convened a second Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee meeting to discuss Amylyx Pharmaceuticals’ investigational drug, AMX-0035 (sodium phenylbutyrate/taurursodiol), for the treatment of amyotrophic lateral sclerosis (ALS).
Top